Overview

Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if it is safe and effective to add a new protease inhibitor (PI), 141W94, to an anti-HIV regimen that includes 2 nucleoside reverse transcriptase inhibitors (NRTIs).

Phase:

Phase 3

Details

Lead Sponsor:

Glaxo Wellcome

Treatments:

Amprenavir
HIV Protease Inhibitors
Protease Inhibitors
Reverse Transcriptase Inhibitors